Northeast Pharmaceutical Group Co Ltd (000597) - Total Liabilities
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has total liabilities worth CN¥7.93 Billion CNY (≈ $1.16 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Northeast Pharmaceutical Group Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Northeast Pharmaceutical Group Co Ltd - Total Liabilities Trend (1993–2025)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000597 asset base.
Northeast Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenyang Toly Bread Co Ltd
SHG:603866
|
China | CN¥2.04 Billion |
|
Primax Electronics Ltd
TW:4915
|
Taiwan | NT$30.70 Billion |
|
Redcare Pharmacy NV
F:RDC
|
Germany | €735.10 Million |
|
O-Bank Co Ltd
TW:2897
|
Taiwan | NT$623.75 Billion |
|
Changjiang & Jinggong Steel Building Group Co Ltd
SHG:600496
|
China | CN¥17.25 Billion |
|
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
|
China | CN¥718.92 Million |
|
Quantum Corporation
NASDAQ:QMCO
|
USA | $219.72 Million |
|
Retail Estates - Sicafi
BR:RET
|
Belgium | €903.57 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down Northeast Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Northeast Pharmaceutical Group Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Northeast Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Northeast Pharmaceutical Group Co Ltd (1993–2025)
The table below shows the annual total liabilities of Northeast Pharmaceutical Group Co Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥7.22 Billion ≈ $1.06 Billion |
-18.67% |
| 2024-12-31 | CN¥8.88 Billion ≈ $1.30 Billion |
-12.24% |
| 2023-12-31 | CN¥10.11 Billion ≈ $1.48 Billion |
+11.19% |
| 2022-12-31 | CN¥9.10 Billion ≈ $1.33 Billion |
+2.34% |
| 2021-12-31 | CN¥8.89 Billion ≈ $1.30 Billion |
+10.51% |
| 2020-12-31 | CN¥8.04 Billion ≈ $1.18 Billion |
-6.71% |
| 2019-12-31 | CN¥8.62 Billion ≈ $1.26 Billion |
+6.11% |
| 2018-12-31 | CN¥8.13 Billion ≈ $1.19 Billion |
+1.01% |
| 2017-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
+9.37% |
| 2016-12-31 | CN¥7.36 Billion ≈ $1.08 Billion |
+16.92% |
| 2015-12-31 | CN¥6.29 Billion ≈ $920.66 Million |
+8.26% |
| 2014-12-31 | CN¥5.81 Billion ≈ $850.43 Million |
-2.42% |
| 2013-12-31 | CN¥5.96 Billion ≈ $871.48 Million |
+40.36% |
| 2012-12-31 | CN¥4.24 Billion ≈ $620.88 Million |
+2.74% |
| 2011-12-31 | CN¥4.13 Billion ≈ $604.29 Million |
+16.65% |
| 2010-12-31 | CN¥3.54 Billion ≈ $518.05 Million |
-12.05% |
| 2009-12-31 | CN¥4.03 Billion ≈ $589.03 Million |
+59.14% |
| 2008-12-31 | CN¥2.53 Billion ≈ $370.14 Million |
+16.99% |
| 2007-12-31 | CN¥2.16 Billion ≈ $316.38 Million |
+68.91% |
| 2006-12-31 | CN¥1.28 Billion ≈ $187.31 Million |
-8.43% |
| 2005-12-31 | CN¥1.40 Billion ≈ $204.54 Million |
-9.84% |
| 2004-12-31 | CN¥1.55 Billion ≈ $226.86 Million |
-6.13% |
| 2003-12-31 | CN¥1.65 Billion ≈ $241.66 Million |
-8.64% |
| 2002-12-31 | CN¥1.81 Billion ≈ $264.52 Million |
-3.47% |
| 2001-12-31 | CN¥1.87 Billion ≈ $274.02 Million |
+6.18% |
| 2000-12-31 | CN¥1.76 Billion ≈ $258.08 Million |
+1.85% |
| 1999-12-31 | CN¥1.73 Billion ≈ $253.39 Million |
+8.84% |
| 1998-12-31 | CN¥1.59 Billion ≈ $232.81 Million |
+29.30% |
| 1997-12-31 | CN¥1.23 Billion ≈ $180.06 Million |
-41.48% |
| 1996-12-31 | CN¥2.10 Billion ≈ $307.68 Million |
+25.37% |
| 1995-12-31 | CN¥1.68 Billion ≈ $245.42 Million |
+50.97% |
| 1994-12-31 | CN¥1.11 Billion ≈ $162.56 Million |
+5.56% |
| 1993-12-31 | CN¥1.05 Billion ≈ $154.01 Million |
-- |
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali … Read more